Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-026-08003-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Saul Martinez-Horta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain. Hauptthemen laut MEDLINE: Huntington Disease, Positron-Emission Tomography, tau Proteins, Thiazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundació Institució dels Centres de Recerca de Catalunya.
Abstract (Originalsprache)
Purpose
Neuropathological and biomarker evidence implicates tau dysregulation as a downstream component of Huntington’s disease (HD) pathobiology, yet its in vivo distribution has not been characterised using second-generation tau-PET tracers. We aimed to define the regional organisation, stage dependence and clinical relevance of tau-sensitive PET signal across the HD disease spectrum.
Methods
Fifty-four participants (13 healthy controls, 9 premanifest mutation carriers and 32 manifest carriers) underwent 60-minute dynamic [¹⁸F]PI-2620 PET imaging. Tau-PET signal was quantified using distribution volume ratios (DVR) derived from reference-tissue kinetic modelling. Analyses combined region-of-interest and whole-brain mapping with threshold-based positivity profiling, modelling of cumulative genetic disease burden (CAP), and clinico-anatomical association analyses.
Results
Tau-PET abnormalities showed a spatially ordered pattern dominated by subcortical involvement. The globus pallidus exhibited the strongest effect, with marked DVR increases and high positivity rates emerging in premanifest carriers and approaching saturation in manifest HD. Additional subcortical changes involved the putamen, whereas caudate DVR decreased in manifest disease. Cortical effects were more modest and selectively involved posterior associative regions. CAP modelling supported predominantly monotonic subcortical stage-related profiles, while limbic and cortical regions showed heterogeneous cross-sectional patterns. Clinico-anatomical analyses linked subcortical tau-PET signal with genetic burden and motor severity and limbic signal with psychiatric symptoms.
Conclusion
Tau-sensitive PET signal represents a spatially ordered and stage-dependent feature of HD and identifies a reproducible pallidal signature linked to disease burden, supporting its potential as a biomarker for patient stratification and mechanistic monitoring in therapeutic studies targeting downstream pathological processes. Trial registration number NCT07503743.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain.
- Research Institute Sant Pau (IR-Sant Pau), Centre CERCA, Barcelona, Spain.
- Centro de Investigación Biomédica en Red-Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
- European Huntington's Disease Network (EHDN), Ulm, Germany.
- Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Förderung
- Fundació Institució dels Centres de Recerca de Catalunya
Zitieren
APA
Martinez-Horta, S., Perez-Perez, J., Puig-Davi, A., Camacho, V., Perez-Carasol, L., Franch-Marti, C., Olmedo-Saura, G., Fernandez-Leon, A., Flotats, A., Kolinger, G. D., Bullich, S., Perez-Martinez, E., Pagonabarraga, J., & Kulisevsky, J. (2026). Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08003-0
Vancouver
Martinez-Horta S, Perez-Perez J, Puig-Davi A, Camacho V, Perez-Carasol L, Franch-Marti C, et al. Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08003-0
BibTeX
@article{MartinezHorta2026,
author = {Martinez-Horta, Saul and Perez-Perez, Jesus and Puig-Davi, Arnau and Camacho, Valle and Perez-Carasol, Laura and Franch-Marti, Carla and Olmedo-Saura, Gonzalo and Fernandez-Leon, Alex and Flotats, Albert and Kolinger, Guilherme D and Bullich, Santiago and Perez-Martinez, Esther and Pagonabarraga, Javier and Kulisevsky, Jaime},
title = {Stage-dependent tau-PET signatures in Huntington’s disease revealed by [¹⁸F]PI-2620},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-026-08003-0}
}
EUVIMED